A Phase 2-3, Multicentre, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
This is a randomized, multicentre, double-blind, placebo-controlled, Phase 2-3 study of
patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately
245 total patients will be randomized to study treatment (selinexor or placebo).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society